Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Epidemiol Infect ; 134(3): 506-13, 2006 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16638164

RESUMEN

This study analysed the role of several risk factors for hospitalization due to community-acquired, respiratory syncytial virus (RSV) infection. The risk factors detected in infants hospitalized for RSV infection in the first 24 months of life were compared with those in the general infant population in our region. There were 361 episodes of hospitalization in 357 infants. Eighty per cent of the infants did not present underlying conditions for severe RSV infection and only 10 (3%) were candidates for palivizumab prophylaxis. In multivariate analysis, birthweight of <2500 g was independently associated with hospitalization for RSV infection and was the most commonly detected medical risk factor. Other risk factors were maternal age at delivery <25 years, birth in the second half of the year, prematurity, suburban residence and congenital heart disease. In conclusion, together with well-known risk factors, we found that low birthweight was an independent factor for severe RSV infection.


Asunto(s)
Hospitalización/estadística & datos numéricos , Infecciones por Virus Sincitial Respiratorio/complicaciones , Adulto , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Cardiopatías Congénitas/complicaciones , Humanos , Lactante , Recién Nacido de Bajo Peso , Recién Nacido , Edad Materna , Análisis Multivariante , Palivizumab , Nacimiento Prematuro , Infecciones por Virus Sincitial Respiratorio/prevención & control , Estudios Retrospectivos , Factores de Riesgo , España
2.
An Pediatr (Barc) ; 59(3): 229-33, 2003 Sep.
Artículo en Español | MEDLINE | ID: mdl-12975114

RESUMEN

BACKGROUND: The complications of varicella are one of the arguments in favor of universal vaccination programs in children. OBJECTIVE: To describe the complications of varicella requiring hospital admission in a well-defined population (Gipuzkoa, Spain) and to compare the incidence of hospitalization with that reported in other series. MATERIAL AND METHODS: Observational, retrospective, multicenter study of admissions for varicella. The medical histories codified as varicella (minimum data set, CIE-0, codes 952.0-052.9) from 1 January 1993 to 31 December 2002 were reviewed. Calculation of hospitalization rates was based on emergency department visits and population data. The pediatric population of Gipuzkoa seeking medical attention at one of the four Basque Country Health Service hospitals in the area: Hondarribia, Mendaro, San Sebastian and Zumarraga. The mean coverage in Gipuzkoa is 54,999 children aged less than 15 years/year. All the children aged 0-15 years old admitted for more than 24 h with a discharge diagnosis of varicella complications. The variables studied are: age, gender, personal history, varicella immunization, immune status, fever, chest X-ray, complementary investigations, length of hospital stay, treatment, discharge diagnosis, clinical course, complications and sequelae at discharge. RESULTS: Seventy-one children were hospitalized. None had been vaccinated against the varicella-zoster virus. Eighty percent were aged less than 5 years and three were immunocompromised. Fifty-six percent had bacterial superinfection and invasive forms were found in seven patients. The mean length of admission was 6.5 days +/- 5.1. No deaths or sequelae were reported. CONCLUSIONS: The annual incidence rate of admissions longer than 24 hours due to varicella complications was 12.9 cases per 100,000 children aged less than 15 years, representing 0.31% of all annual admissions in this age group.


Asunto(s)
Infecciones Bacterianas/etiología , Varicela/complicaciones , Varicela/rehabilitación , Enfermedades Hematológicas/etiología , Enfermedades del Sistema Nervioso/etiología , Adolescente , Infecciones Bacterianas/epidemiología , Varicela/epidemiología , Niño , Preescolar , Servicios Médicos de Urgencia/estadística & datos numéricos , Femenino , Enfermedades Hematológicas/epidemiología , Hospitalización/estadística & datos numéricos , Humanos , Lactante , Recién Nacido , Masculino , Enfermedades del Sistema Nervioso/epidemiología , Estudios Retrospectivos , España/epidemiología
3.
Enferm Infecc Microbiol Clin ; 15(5): 255-9, 1997 May.
Artículo en Español | MEDLINE | ID: mdl-9376383

RESUMEN

BACKGROUND: The aim of this study was to determine the effect of ciprofloxacin at subinhibitory concentrations on the expression of P fimbriae of uropathogenic Escherichia coli. Thirty-nine strains of Escherichia coli isolated from out patients with urinary tract infection were studied. Thirty-nine of these strains had been previously characterized as P-fimbriated and the remaining non fimbriated strain was used as a negative control. METHODS: Fimbriation was quantitatively studied by electron microscope observation of the strains before and after treatment. To determine possible qualitative variations in the fimbrial proteins and in the external membrane (OMPs), extraction and electrophoretic separation was performed in polyacrylamide gels. RESULTS: No qualitative differences were observed in the OMPs profile and fimbrial proteins induced by ciprofloxacin in any of the strains studied. However, electron microscopic observation generally showed a decrease in the percentage fimbriated bacterial cells by the antimicrobial effect. CONCLUSIONS: The mechanism of action of ciprofloxacin at subinhibitory doses may correspond to a process of fimbrial protein synthesis inhibition secondary to the initiation of general repair mechanism of the cell exposed to the antimicrobial and not to a process of specific mutations which qualitatively affect fimbrial protein composition.


Asunto(s)
Antiinfecciosos/farmacología , Ciprofloxacina/farmacología , Escherichia coli/efectos de los fármacos , Fimbrias Bacterianas/efectos de los fármacos , Antiinfecciosos/uso terapéutico , Adhesión Bacteriana/efectos de los fármacos , Proteínas de la Membrana Bacteriana Externa/biosíntesis , Proteínas de la Membrana Bacteriana Externa/genética , Ciprofloxacina/uso terapéutico , Escherichia coli/clasificación , Escherichia coli/crecimiento & desarrollo , Escherichia coli/aislamiento & purificación , Escherichia coli/patogenicidad , Escherichia coli/ultraestructura , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , Humanos , Serotipificación , Infecciones Urinarias/microbiología , Virulencia/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA